Delivery Order SPE2DB20D3103-SPE2DB25FP7R2
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $26,154.99 to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of RINVOQ ER 30 mg tablets (quantity: 30-unit bottles). This is a firm fixed price, competitively awarded contract with no set-aside designation and a completion date of July 23, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $37,029.83 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on May 30, 2025, with an ultimate completion date of June 2, 2025. This competitively awarded, non-set-aside contract employs firm fixed pricing and is being fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order valued at $28,637.88 to AmerisourceBergen Drug Corp for RINVOQ ER 45 mg tablets (28-unit pack) on August 29, 2025, with completion targeted for September 2, 2025. This firm fixed-price contract, issued without set-aside designation, represents a competitive award to the pharmaceutical distributor headquartered in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $80,832.18 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 45 mg tablets (28-count units) on July 22, 2025, with completion scheduled for July 23, 2025. This firm fixed-price, competitively awarded contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The contract involves no set-aside...
- The Defense Logistics Agency awarded a $32,046.35 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on July 22, 2025, with completion targeted for July 23, 2025. This non-competitive, non-set-aside delivery order represents a child contract action under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 prime vendor agreement valued through December 2026. The product will...
- The Defense Logistics Agency awarded a $42,773.33 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on July 23, 2025, with an ultimate completion date of July 24, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The place of performance is listed...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $17,605.35 on August 20, 2025, for the supply of RINVOQ ER 30 mg tablets (30-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 21, 2025. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is a child contract...
- The Defense Logistics Agency awarded a delivery order valued at $13,364.72 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets in quantities of 30 units. This firm fixed price, competitively awarded contract was issued on July 21, 2025, with an ultimate completion date of July 22, 2025. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends...
- The Defense Logistics Agency awarded a $29,602.52 delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for RINVOQ ER 15 mg tablets (30-count units). This firm fixed-price, competitively awarded contract is not set-aside and carries an ultimate completion date of August 12, 2025. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 prime vendor agreement valued through...
- The Defense Logistics Agency awarded a $3,678.58 firm fixed price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on April 23, 2025, with an ultimate completion date of April 24, 2025. This delivery order represents a child contract under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026 that enables the company to supply pharmaceutical...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FP7R2Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $48,759.91 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on August 6, 2025, with a completion date of August 7, 2025. The contract carries a firm fixed price structure with no set-aside designation, indicating competitive award through open procurement. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the delivery at its corporate office location. This delivery order represents a child contract under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. As a critical vendor in the federal medical supply chain, AmerisourceBergen supplies a broad portfolio of pharmaceutical products and medical commodities to support military and veteran healthcare systems. The company's delivery of RINVOQ ER, a rheumatoid arthritis medication, exemplifies its role in providing specialized pharmaceutical treatments across multiple therapeutic domains. Through its prime vendor contract with DLA, AmerisourceBergen serves the Defense Health Agency, U.S. Coast Guard, and other government healthcare entities, ensuring consistent access to both brand-name and generic medications necessary for military medical operations worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $48.8k | 8/6/25 |